Johns Hopkins Medicine is currently seeking participants for a groundbreaking clinical trial investigating the potential effects of psilocybin, the psychoactive compound found in “magic mushrooms”, on adults diagnosed with ADHD.
The study, led by Principal Investigator Roland Griffiths, PhD, is open to individuals aged 18-65 who meet the criteria for ADHD.
This research aims to explore whether psilocybin can provide therapeutic benefits for those struggling with ADHD, a condition often characterized by inattention, hyperactivity, and impulsiveness. Psilocybin has garnered significant attention in recent years for its potential to treat various mental health conditions, including depression and anxiety. This study represents one of the first efforts to examine its effects on ADHD.
Continue reading